Overall Congress Learning Objectives:
Following the program, participants will be able to:
-
Describe the latest approaches to diagnosis and treatment of Heart Failure due to Preserved EF (communicator, leader)
-
Understand clinical scenarios for consideration of special cardiomyopathies (scholar, medical expert)
-
Use practical and efficient approaches to treatment of HF due to Reduced EF (collaborator, professional)
-
Describe novel drugs and devices for treatment of heart failure (communicator, health advocate)
Please note that all times are set to Eastern Time (ET) (UTC-4)
8:00 a.m.
|
Breakfast Buffet Opens
|
|
8:30 - 9:30 a.m. ET
|
BREAKFAST SYMPOSIUM (unaccredited)
|
|
PLENARY SESSION 3:
Canadian Heart Failure Society (CHFS) & Heart Failure
Association of the ESC (HFA) Joint Plenary Session PREVENTING RECURRENT HOSPITALIZATIONS |
||
9:40 a.m.
|
Plenary Opening Remarks
|
|
9:55 a.m.
|
Worsening HF: What is it and Why is it Important?
|
|
10:10 a.m.
|
Diuretics and 'New' Drugs in AHF
|
|
10:25 a.m.
|
Managing AF in Acute HF
|
|
10:40 a.m.
|
Identifying the 'Sweet Spot' for Invasive Hemodynamic Monitoring
|
|
10:55 a.m.
|
Plenary Q&A
|
|
SÉANCE PLÉNIÈRE 3:
PRÉVENIR LES HOSPITALISATIONS RÉCURRENTES
|
||
9:40 a.m.
|
Mots de bienvenue
|
|
9:55 a.m.
|
Détérioration clinique de l’insuffisance cardiaque : pathophysiologie et importance clinique
|
|
10:10 a.m.
|
Approche à l’insuffisance cardiaque aiguë : Diurétique et nouvelles avenues de traitement
|
|
10:25 a.m.
|
Prise en charge de la FA en ADHF
|
|
10:40 a.m.
|
Utilisation judicieuse du monitoring invasif
|
|
10:55 a.m.
|
Questions-réponses en plénière
|
|
11:15 a.m.
|
BREAK (for in person delegates)
|
|
11:20 - 11:40 a.m.
|
CORRIDOR CONSULTS (for online delegates) Unaccredited – Choose to Attend one of our Engaging Faculty-Lead Sessions
|
|
WORKSHOPS
Choose one to Attend
|
||
11:45 a.m. - 12:30 p.m.
|
1. Special Cardiomyopathies: Focus on Treatment
|
|
11:45 a.m. - 12:30 p.m.
|
2. Treatment of Refractory HF
|
|
11:45 a.m. - 12:30 p.m.
|
3. Managing Depression in Heart Failure
|
|
11:45 a.m. - 12:30 p.m.
|
4. Practically Starting and Stopping GDMT
|
|
12:30 p.m.
|
Lunch Buffet Opens
|
|
12:50 - 1:50 p.m.
|
LUNCH SYMPOSIUM (unaccredited)
|
|
PLENARY 4:
Canadian Heart Failure Society (CHFS) & Heart Failure Society of America (HFSA)
Joint Plenary Session CUTTING EDGE HF THERAPIES |
||
2:00 p.m.
|
Presentation of Awards: CHFN & Trainee Research Competition
|
|
2:10 p.m.
|
Plenary Opening Remarks
|
|
2:15 p.m.
|
Has COVID-19 Taught us Anything about HF?
|
|
2:30 p.m.
|
New Devices for HF
|
|
2:45 p.m.
|
Successes and Challenges with Percutaneous Valve Therapy
|
|
3:00 p.m.
|
Challenges with ''Destination Therapy" in Canada
|
|
3:15 p.m.
|
Plenary Q&A
|
|
3:35 p.m.
|
Congress Closing Remarks
|
|
3:45 - 4:05 p.m.
|
Day 2 Highlights From our Co-Chairs
|